Overview

An IIT Clinical Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of a Single Intrathecal Injection of SNUG01 in Patients with Amyotrophic Lateral Sclerosis

Status:
NOT_YET_RECRUITING

Trial end date:
2029-10-15

Target enrollment:

Participant gender:

Summary

This is a multicenter, open-label, single-arm investigator-initiated clinical study designed to evaluate the safety, tolerability, and preliminary efficacy of SNUG01 in patients with Amyotrophic Lateral Sclerosis (ALS).

Phase:

EARLY_PHASE1

Details

Lead Sponsor:

Peking University Third Hospital

Collaborator:

SineuGene Therapeutics Co., Ltd.